Squamous Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Conditions: Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Or...
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma Interventions: Drug: ABBV-400 Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

Toripalimab in Combined With Cetuximab ，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
Conditions: Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Toripalimab Sponsors: First Affiliated Hospital of Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Zanzalintinib; Drug: Zanzalintinib-matched Placebo; Biological: Pembrolizumab Sponsors: Exelixis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Penpulimab injection; Drug: cisplatin; Drug: albumin-paclitaxel Sponsors: Shanghai Ninth People ' s Hospital Affiliated to Shanghai Jiao Tong University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
Conditions: Esophageal Squamous Cell Carcinoma (ESCC); PD-1 Inhibitors Interventions: Drug: IBI110+Sintilimab Sponsors: The First Affiliated Hospital of Zhengzhou University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials

Molecular Characterization of Penile Cancers in Developing Countries
Conditions: Penile Squamous Cell Carcinoma Sponsors: Latin American Cooperative Oncology Group; Roche Pharma AG Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma Interventions: Biological: Ficlatuzumab; Biological: Cetuximab; Other: Placebo Sponsors: AVEO Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: 1% Lugol ' s iodine solution; Drug: 5% Lugol ' s iodine solution Sponsors: Xijing Hospital of Digestive Diseases; Ankang Central Hospital; The First Affiliated Hospital of ShiheziI University; Xi ' an International Medical Center Hospital; Air Force 986 Hospital; Xianyang Central Hospital (the second people ' s Hospital of Xianyang City) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Neoplasms, Head and Neck Interventions: Drug: Dostarlimab; Drug: Belrestotug; Drug: GSK6097608 Sponsors: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: TAK-676; Drug: Carboplatin; Drug: 5-FU; Drug: Paclitaxel; Combination Product: TAK-676 + Carboplatin; Combination Product: Carboplatin + Paclitaxel; Combination Product: Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + Paclitaxel Sponsors: Presage Biosciences; Takeda Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials

Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Conditions: Squamous Cell Carcinoma of the Oropharynx Interventions: Procedure: Tumor Biopsy Sponsors: Fondation H ôpital Saint-Joseph Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
Conditions: Esophageal Cancer Interventions: Other: follow up Sponsors: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Intervention: Drug: Tislelizumab Sponsor: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Conditions: HIV Infections; Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma Interventions: Other: Group Meeting (Focus Group); Other: Questionnaires Sponsors: University of California, San Francisco; National Institute of Dental and Craniofacial Research (NIDCR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials